Marx, Mathieu
Costa, Nadège
Lepage, Benoit
Taoui, Soumia
Molinier, Laurent
Deguine, Olivier
Fraysse, Bernard
Funding for this research was provided by:
Direction Générale de l’offre de Soins (13 7053 10)
Article History
Received: 6 September 2018
Accepted: 9 January 2019
First Online: 4 February 2019
Ethics approval and consent to participate
: All of the authorisations required in accordance with French legislation were obtained for this study: “Agence Nationale de Sécurité du Médicament” (ANSM, National Agency of Drug Safety) (authorisation dated May 2014), and approved by the “Commission Nationale Informatique et Libertés” (CNIL, French National Agency regulating Data Protection). This study was presented to the South-West and Overseas territories’ Ethics Committee on May 2014. All of the patients taking part in this clinical trial have received verbal and written information and have been able to ask questions about the study. They willingly signed an informed consent form before starting the trial.
: Not applicable. No private information of patients will be published.
: The authors declare that they have no competing interests.
: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.